San Francisco Sentry Investment Group’s Clovis Oncology, Inc. CLVS Stock Holding History

San Francisco Sentry Investment Group’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$3K	Hold	600	–	–	﹤0.01%	621
2021 Q1	$4K	Hold	600	–	–	﹤0.01%	623
2020 Q4	$3K	Hold	600	–	–	﹤0.01%	612
2020 Q3	$3K	Hold	600	–	–	﹤0.01%	591
2020 Q2	$4K	Hold	600	–	–	﹤0.01%	556
2020 Q1	$4K	Hold	600	–	–	﹤0.01%	595
2019 Q4	$6K	Hold	600	–	–	﹤0.01%	624
2019 Q3	$2K	Hold	600	–	–	﹤0.01%	781
2019 Q2	$9K	Hold	600	–	–	﹤0.01%	569
2019 Q1	$15K	Hold	600	–	–	0.01%	527
2018 Q4	$11K	Buy	600 +200	+50%	+$4.09K	0.01%	559
2018 Q3	$12K	Hold	400	–	–	﹤0.01%	563
2018 Q2	$18K	Hold	400	–	–	0.01%	514
2018 Q1	$21K	Hold	400	–	–	0.01%	575
2017 Q4	$27K	Buy	400 +100	+33%	+$6.99K	0.01%	524
2017 Q3	$25K	Buy	+300	New	+$23.8K	0.01%	522

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

San Francisco Sentry Investment Group's CLVS Position: Q2 2021 in Review

San Francisco Sentry Investment Group held its Clovis Oncology, Inc. (CLVS) position steady in Q2 2021 at 600 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #621.

San Francisco Sentry Investment Group first reported a position in CLVS in Q3 2017 and has held it in 16 quarters since. The position peaked at $27K in Q4 2017. 160 funds tracked by Wall St. Rank hold CLVS as of Q2 2021.

San Francisco Sentry Investment Group held 600 shares of Clovis Oncology, Inc. worth $3K as of Q2 2021.
San Francisco Sentry Investment Group left its Clovis Oncology, Inc. share count unchanged in Q2 2021.
Clovis Oncology, Inc. made up ﹤0.01% of San Francisco Sentry Investment Group's portfolio in Q2 2021, its #621 holding.
San Francisco Sentry Investment Group first reported a position in Clovis Oncology, Inc. in Q3 2017 and has held it in 16 quarters since.
San Francisco Sentry Investment Group's Clovis Oncology, Inc. position peaked at $27K in Q4 2017.
160 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2021.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2021, filed 2 Aug 2021.